| Name | Title | Contact Details |
|---|---|---|
Kieran Byrne |
Executive Director, Ethics and Compliance | Profile |
Fumiaki Sakurai |
Chief Administrative Officer and Chief Ethics and Compliance Officer | Profile |
Katsuyoshi Sugita |
Chief Ethics and Compliance Officer | Profile |
Jim Lynch |
Associate General Counsel | Profile |
Bianca Thomae |
Associate General Counsel | Profile |
We want to share our innovations with you and learn from your feedback. Help us improve quality and design to make sure your system delivers from day one.
Minakem is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Prepak Systems is a Cookeville, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
U.S. Urology Partners is a physician-led management services organization that provides business support services to our network of urology practices .